Phase 1 Rheumatoid Arthritis Trial, Recruiting NCT07100873 Sponsor: Adicet Therapeutics Condition: Rheumatoid Arthritis
Back to Rheumatoid Arthritis

Phase 1 Rheumatoid Arthritis Trial, Recruiting

NCT07100873
Recruiting Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are 18 years of age or older
  • People who have been diagnosed with rheumatoid arthritis according to a recognised set of medical classification standards (the 2010 ACR-EULAR criteria — confirm with trial site if unsure whether this applies)
  • People who agree not to take traditional medicines or any medications that have not been prescribed by a doctor
  • People who have adequate function of the blood, liver, heart, and lungs as determined by testing

Who may not be able to join:

  • People who have severe liver disease classified as Child-Pugh class B or C (a medical grading system for liver health — confirm with trial site)
  • People who have an autoimmune disease that requires a relatively high daily dose of prednisone or a similar steroid medication (specifically more than 0.5 mg per kilogram of body weight per day)
  • People who are not willing to take part in an extended safety monitoring period after the main part of the trial ends
  • People who have had a serious infection — such as a severe blood infection, pneumonia, fungal, viral, or other significant infection — within the four weeks before the first dose of the study treatment, if the trial doctors believe this could affect their safety during the study

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 20 July 2026
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 021-61673760

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 1
Sponsor
Adicet Therapeutics
Registry
ClinicalTrials.gov
Start date
10 October 2025
Est. completion
30 March 2027

Where this trial is recruiting

🇨🇳 China

Primary endpoints

The Incidence of Subjects with Dose Limiting Toxicities within each dose level cohort

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov